NCT00004801已完成1 期
Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency
National Center for Research Resources (NCRR)0 个研究点目标入组 3 人开始时间: 1992年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
OBJECTIVES:
Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients with factor IX deficiency.
详细描述
PROTOCOL OUTLINE:
Patients receive monoclonal factor IX replacement therapy as inpatients. Patients with a satisfactory response receive further therapy as needed for bleeding for up to 36 months at home.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •Patients with factor IX deficiency.
排除标准
- 未提供
研究者
相似试验
终止
3 期
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia BHemophilia BNCT01271868Medexus Pharma, Inc.9
已完成
1 期
A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia BHemophilia BNCT01361126CSL Behring17
已完成
4 期
IMMUNINE Pre-Treatment StudyHemophilia BNCT01128881Baxalta now part of Shire57
已完成
3 期
Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B PatientsHemophilia BNCT01174446Baxalta now part of Shire86
进行中（未招募）
1 期
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia BHemophilia BNCT01687608Baxalta now part of Shire30